The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady supply of critical cancer treatments to serve veteran patients nationwide.
Janssen Biotech also holds a $3.1 billion multiple-award Federal Supply Schedule (FSS-61-IB) contract with the VA for a broad range of pharmaceutical products. The BPA call orders and FSS contract enable various VA Veterans Integrated Service Networks (VISNs) to efficiently order and receive these oncology drugs on an as-needed basis, often for emergency patient care requirements. These contract awards do not include any set-aside designations, reflecting Janssen Biotech's status as a large, for-profit manufacturer.
Generated 9/13/24, 9:09 AM